---
title: "SciSparc Ltd. (SPRC.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SPRC.US.md"
symbol: "SPRC.US"
name: "SciSparc Ltd."
industry: "Pharmaceuticals"
---

# SciSparc Ltd. (SPRC.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [cisparc.com](https://cisparc.com) |

## Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepti...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:13.000Z

**Overall: D (0.71)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 187.98% |  |
| Net Profit YoY | -172.15% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.59M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.31M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1375.72% | E |
| Profit Margin | -4294.64% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -14.44% | E |
| Net Profit YoY | -837.30% | E |
| Total Assets YoY | 0.00% | C |
| Net Assets YoY | -100.00% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -2.33% | D |
| OCF YoY | -14.44% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 0.00% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - SciSparc Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1375.72%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4294.64%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-14.44%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-837.30%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-2.33%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-14.44%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "0.00%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | E | A | B | B |
| 02 | Johnson & Johnson (US.JNJ) | A | B | E | A | C | B |
| 03 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 04 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 05 | AstraZeneca (US.AZN) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.40 | 82/256 | - | - | - |
| PB | -5.10 | - | 0.46 | 0.36 | 0.17 |
| PS (TTM) | 1.99 | 51/256 | 3.27 | 2.56 | 0.90 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2022-04-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.60 |

## References

- [Company Overview](https://longbridge.com/en/quote/SPRC.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SPRC.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SPRC.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
